Yupeng Li1, Perttu Niemela2, Li Liao3, Shengpeng Jiang4, Heng Li5, Falk Poenisch5, X Ronald Zhu5, Sami Siljamaki2, Reynald Vanderstraeten2, Narayan Sahoo5, Michael Gillin5, Xiaodong Zhang5. 1. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 and Department of Applied Research, Varian Medical Systems, Palo Alto, California 94304. 2. Department of Applied Research, Varian Medical Systems, Palo Alto, California 94304. 3. Department of Industrial Engineering, University of Houston, Houston, Texas 77004. 4. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 and Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300040, China. 5. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030.
Abstract
PURPOSE: To develop a new robust optimization strategy for intensity-modulated proton therapy as an important step in translating robust proton treatment planning from research to clinical applications. METHODS: In selective robust optimization, a worst-case-based robust optimization algorithm is extended, and terms of the objective function are selectively computed from either the worst-case dose or the nominal dose. Two lung cancer cases and one head and neck cancer case were used to demonstrate the practical significance of the proposed robust planning strategy. The lung cancer cases had minimal tumor motion less than 5 mm, and, for the demonstration of the methodology, are assumed to be static. RESULTS: Selective robust optimization achieved robust clinical target volume (CTV) coverage and at the same time increased nominal planning target volume coverage to 95.8%, compared to the 84.6% coverage achieved with CTV-based robust optimization in one of the lung cases. In the other lung case, the maximum dose in selective robust optimization was lowered from a dose of 131.3% in the CTV-based robust optimization to 113.6%. Selective robust optimization provided robust CTV coverage in the head and neck case, and at the same time improved controls over isodose distribution so that clinical requirements may be readily met. CONCLUSIONS: Selective robust optimization may provide the flexibility and capability necessary for meeting various clinical requirements in addition to achieving the required plan robustness in practical proton treatment planning settings.
PURPOSE: To develop a new robust optimization strategy for intensity-modulated proton therapy as an important step in translating robust proton treatment planning from research to clinical applications. METHODS: In selective robust optimization, a worst-case-based robust optimization algorithm is extended, and terms of the objective function are selectively computed from either the worst-case dose or the nominal dose. Two lung cancer cases and one head and neck cancer case were used to demonstrate the practical significance of the proposed robust planning strategy. The lung cancer cases had minimal tumor motion less than 5 mm, and, for the demonstration of the methodology, are assumed to be static. RESULTS: Selective robust optimization achieved robust clinical target volume (CTV) coverage and at the same time increased nominal planning target volume coverage to 95.8%, compared to the 84.6% coverage achieved with CTV-based robust optimization in one of the lung cases. In the other lung case, the maximum dose in selective robust optimization was lowered from a dose of 131.3% in the CTV-based robust optimization to 113.6%. Selective robust optimization provided robust CTV coverage in the head and neck case, and at the same time improved controls over isodose distribution so that clinical requirements may be readily met. CONCLUSIONS: Selective robust optimization may provide the flexibility and capability necessary for meeting various clinical requirements in addition to achieving the required plan robustness in practical proton treatment planning settings.
Authors: Wenbo Gu; Dan Ruan; Daniel O'Connor; Wei Zou; Lei Dong; Min-Yu Tsai; Xun Jia; Ke Sheng Journal: Med Phys Date: 2019-01-21 Impact factor: 4.071
Authors: Li Liao; Gino J Lim; Yupeng Li; Juan Yu; Narayan Sahoo; Heng Li; Michael Gillin; X Ronald Zhu; Anita Mahajan; Steven J Frank; David R Grosshans; Quynh-Nhu Nguyen; Daniel Gomez; Xiaodong Zhang Journal: Int J Part Ther Date: 2016-12-30
Authors: Christina Hague; Marianne Aznar; Lei Dong; Alireza Fotouhi-Ghiam; Lip Wai Lee; Taoran Li; Alexander Lin; Matthew Lowe; John N Lukens; Andrew McPartlin; Shannon O'Reilly; Nick Slevin; Samuel Swisher-Mcclure; David Thomson; Marcel Van Herk; Catharine West; Wei Zou; Boon-Keng Kevin Teo Journal: Br J Radiol Date: 2019-12-23 Impact factor: 3.039